Evidence map›Paper›PMID 42870854›Full record

ArticleTranslational lung cancer research2026

Association of baseline hormone levels with outcomes of first-line immunotherapy in extensive-stage small cell lung cancer.

Shuxing Wang, Rui Meng, Jiheng Liu, Yang Zhao, Qian Sui, Yiyang Li, Dan Fan, Min Lu, Yue Zeng, Lu Chen and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Shuxing WangDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Rui MengCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jiheng LiuDepartment of Hematology & Oncology, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, China.
Yang ZhaoDepartment of Oncology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Qian SuiDepartment of Hematology & Oncology, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, China.
Yiyang LiDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Dan FanDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Min LuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Yue ZengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Lu ChenDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Zimeng ChenDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Wenxin LiDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Haohui WangDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Shijiao YaoDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Aoxi LiangDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Ji'an ZouXiangya School of Medicine, Central South University, Changsha, China.
Yurong PengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Xuecheng LiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhenhua QiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Fang WuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-6627-3437

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Endocrine dysregulation may influence immune function and clinical outcomes in cancer. This study investigated the prognostic relevance of baseline endocrine hormones in patients with extensive-stage small cell lung cancer (ES-SCLC) receiving first-line immunotherapy. Methods: This retrospective multicenter cohort study included patients with ES-SCLC treated at multiple centers between January 2020 and December 2024. Baseline serum levels of cortisol, adrenocorticotropic hormone (ACTH), free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were measured before treatment. Patients were stratified into high and low groups for each hormone based on median values. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. Results: A total of 377 patients were included, with a median PFS of 9.7 months and median OS of 16.7 months. Patients with high baseline cortisol had significantly shorter PFS (8.9 Conclusions: Baseline cortisol is independently associated with survival outcomes in ES-SCLC patients receiving immunotherapy and may serve as a prognostic biomarker. These findings highlight the relevance of neuroendocrine-immune interactions and warrant prospective validation.

Indexed as

biomarkercortisolhormonesimmunotherapySmall cell lung cancer (SCLC)

Identifiers

PMID42870854
PMCPMC13657891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.